Paper38020299
Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
Abbas M and 7 others. Oncol Lett, 2023. Cited by 21 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer. Papers, record 38020299. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38020299
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21551320 | Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. | J Histochem Cytochem | 2011 | https://conductscience.org/library/papers/21551320 | PubMed |
| 2 | 28938585 | The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/28938585 | PubMed |
| 3 | 28131785 | Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28131785 | PubMed |
| 4 | 31340094 | Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31340094 | PubMed |
| 5 | 24382958 | Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. | Adv Urol | 2013 | https://conductscience.org/library/papers/24382958 | PubMed |
| 6 | 35118443 | Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies. | touchREV Endocrinol | 2021 | https://conductscience.org/library/papers/35118443 | PubMed |
| 7 | 23070813 | Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. | Genes Dev | 2012 | https://conductscience.org/library/papers/23070813 | PubMed |
| 8 | 27939400 | Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. | Lancet | 2017 | https://conductscience.org/library/papers/27939400 | PubMed |
| 9 | 26952546 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. | Lancet | 2016 | https://conductscience.org/library/papers/26952546 | PubMed |
| 10 | 27269937 | Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27269937 | PubMed |
| 11 | 28709407 | Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways. | BMC Cancer | 2017 | https://conductscience.org/library/papers/28709407 | PubMed |
| 12 | 34768978 | Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34768978 | PubMed |
| 13 | 29989029 | The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. | Oncotarget | 2018 | https://conductscience.org/library/papers/29989029 | PubMed |
| 14 | 24086649 | Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. | PLoS One | 2013 | https://conductscience.org/library/papers/24086649 | PubMed |
| 15 | 32183076 | Epidemiology of Bladder Cancer. | Med Sci (Basel) | 2020 | https://conductscience.org/library/papers/32183076 | PubMed |
| 16 | 33577729 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33577729 | PubMed |
| 17 | 35477165 | Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. | Pathobiology | 2022 | https://conductscience.org/library/papers/35477165 | PubMed |
| 18 | 28967485 | First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28967485 | PubMed |
| 19 | 29901071 | Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells. | Int J Oncol | 2018 | https://conductscience.org/library/papers/29901071 | PubMed |
| 20 | 35735421 | Trop-2 in Upper Tract Urothelial Carcinoma. | Curr Oncol | 2022 | https://conductscience.org/library/papers/35735421 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42729864 | Structure and function of therapeutic antibodies approved by the US FDA in 2025. | Antib Ther | 2026 | https://conductscience.org/library/papers/42729864 | PubMed |
| 42729159 | Disease stage-dependent expression of ADC-related biomarkers in urothelial carcinoma. | Transl Androl Urol | 2026 | https://conductscience.org/library/papers/42729159 | PubMed |
| 42665429 | TROP2 Expression in Bladder Transurethral Resection Specimens: Correlation With Histological Grade and Survival. | In Vivo | 2026 | https://conductscience.org/library/papers/42665429 | PubMed |
| 42137465 | SOX2-positive upper tract urothelial carcinoma: Clinicopathological characteristics and therapeutic implications. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42137465 | PubMed |
| 41680099 | Expression of Nectin-4 and Trop-2 in upper tract urothelial carcinoma: implications for biomarker-driven antibody-drug conjugate therapy. | J Pathol Clin Res | 2026 | https://conductscience.org/library/papers/41680099 | PubMed |
| 41652619 | The emerging role of TROP2 as a diagnostic and prognostic biomarker in bladder tumor. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/41652619 | PubMed |
| 41409251 | Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition. | Front Oncol | 2025 | https://conductscience.org/library/papers/41409251 | PubMed |
| 40931013 | Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. | Nat Commun | 2025 | https://conductscience.org/library/papers/40931013 | PubMed |
| 40688535 | TROP2-targeted molecular imaging: a promising tool for precision oncology. | Am J Nucl Med Mol Imaging | 2025 | https://conductscience.org/library/papers/40688535 | PubMed |
| 40688533 | [89Zr]Zr-DFO-Trodelvy immunoPET for noninvasive Trop2 imaging in bladder cancer. | Am J Nucl Med Mol Imaging | 2025 | https://conductscience.org/library/papers/40688533 | PubMed |
| 40591027 | Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40591027 | PubMed |
| 40526099 | Optimizing enfortumab vedotin plus pembrolizumab therapy. | Oncotarget | 2025 | https://conductscience.org/library/papers/40526099 | PubMed |
| 40316856 | Integrating analysis of multi-omics summary data identifies novel plasma protein biomarkers and drug targets for bladder cancer. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40316856 | PubMed |
| 40059341 | ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [64Cu]Cu-NOTA-Trodelvy. | Mol Pharm | 2025 | https://conductscience.org/library/papers/40059341 | PubMed |
| 39835546 | Exploring the Therapeutic Potential of TROP2 Gene Silencing in Hepatocellular Carcinoma. | Recent Pat Biotechnol | 2026 | https://conductscience.org/library/papers/39835546 | PubMed |
| 39705501 | Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes. | Am J Clin Pathol | 2025 | https://conductscience.org/library/papers/39705501 | PubMed |
| 39280671 | Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer? | Transl Androl Urol | 2024 | https://conductscience.org/library/papers/39280671 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| FGFR3 | 2261 | PubTator's text mining | https://conductscience.org/library/genes/2261 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MAPK8 | 5599 | PubTator's text mining | https://conductscience.org/library/genes/5599 | NCBI Gene |
| NECTIN4 | 81607 | PubTator's text mining | https://conductscience.org/library/genes/81607 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TACSTD2 | 4070 | PubTator's text mining | https://conductscience.org/library/genes/4070 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38020299
GET https://conductscience.org/api/papers/v1/38020299/references?page=2